GTx raises $47.5 M to advance Ostarine in cancer-wasting and partner Capesaris
This article was originally published in Scrip
Executive Summary
GTx Inc on 23 June priced a follow-on public offering of 10 million shares of its common stock at $4.75, for proceeds of about $47.5 million.